Rho guanine nucleotide exchange factors (Rho GEFs) are responsible for Rho protein activation by catalyzing the exchange of GDP for GTP. Although overactivation of Rho proteins is a common component of the pathogenesis of vascular disorders, the molecular mechanisms and the Rho GEFs regulating Rho protein activity and Rho-dependent functions in vascular smooth muscle cells (VSMC) are still unknown. The aim of this study was thus to identify Rho GEFs involved in the regulation of VSMC functions.
Introduction
During the past few years, Rho protein (RhoA, Rac1, Cdc42) signalling pathways have been recognized as major regulators of vascular smooth muscle cell (VSMC) functions and much evidence has been accumulated to implicate Rho protein activation as a common component for the pathogenesis of several cardiovascular disorders including hypertension, coronary and cerebral vasospasm, atherosclerosis, and diabetes. 1 Indeed, although basal Rho protein activity is required for homeostatic functions in physiological conditions, sustained over-activation of Rho protein has pathological consequences in the cardiovascular system. The Rho family proteins, identified as the master regulators of the actin cytoskeleton, control a remarkable diversity of cell functions including contraction, motility, proliferation, and apoptosis. 2 Rho proteins act as molecular switches that are activated when they bind to GTP and inactivated when the nucleotide is hydrolyzed to GDP. 2 This regulatory cycle is controlled by different protein families. In the inactive GDP-bound form, Rho is locked in the cytosol by guanine dissociation inhibitors. GTPase-activating proteins decrease Rho protein activity by stimulating their intrinsic GTP hydrolysis activity. 3 Guanine nucleotide exchange factors (GEFs) increase the activity of Rho proteins by promoting the exchange of GDP for GTP. Almost all Rho GEFs belong to the Dbl-Rho GEF family, characterized by tandem Dbl-homology (DH) and pleckstrin-homology (PH) domains. 4 -6 The Dbl-Rho GEF family comprises approximately 70 members in mammals for only 20 Rho proteins, raising the question of how Rho protein-dependent functions are coordinated and whether Rho GEFs have redundant or specific functions. Examination of the expression of Rho GEFs in arteries from rat models of hypertension or in VSMC has led to conflicting data, as no change, increase, or decrease have been reported. 7 -10 Stimulation of VSMC by angiotensin II (Ang II) has been shown to induce tyrosine phosphorylation of PDZ-Rho GEFs, 11 and surprisingly, of the Rho GEF Vav, 12 although Vav expression was initially described as strictly restricted to haematopoietic cells. 13 However, the consequences of these changes in Rho GEF expression and phosphorylation on Rho proteins activity or Rho-dependent functions in VSMC have not been addressed. Recently, by using knock-out mice, the Rho GEF Larg was found to be involved in salt-induced hypertension 14 and
Vav3 deletion has been reported to induce hypertension through hyperactivity of the sympathetic nervous system. 15 The aim of this study was thus to identify Rho GEFs involved in the regulation of VSMC functions. By functional screening using small silencing RNA (siRNA), we identified, among 27 Rho GEFs, Vav3 as a regulator of VSMC proliferation and migration involved in vascular wall remodelling.
Methods
The investigation conforms with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85 -23, revised 1996) and was approved by our local ethics review board (CEEA Pays de la Loire, no. 0077291C).
Cell culture
VSMC were obtained from explants of rat aorta. Cells were cultured in Dulbecco's Modified Eagle Medium (DMEM) with 10% foetal calf serum (FCS), 100 U/mL penicillin, and 100 mg/mL streptomycin. Only cells at passage 3 were used in this study.
Small interfering RNA
Sequences of mRNA of rat GEFs were identified in the GenBank nucleotide database. Sequences of siRNA and primers targeting the 27 Rho GEFs expressed in VSMC (Supplementary material online, Figure S1 ) and analysed are given in Supplementary material online, Table S1 . The siRNA sequences targeting the different rat Rho GEFs were designed by Eurogentec (Seraing, Belgium) and checked by BLAST search. A universal scrambled siRNA has been used as negative control. The siRNA were introduced into VSMC with Jet PEI reagent (Polytransfection, Illkirch, France) according to the manufacturer's recommendations. Cells were incubated with or without 1.2 mg of specific or scrambled siRNA for 48 h before functional assays were conducted. The efficiency of siRNAmediated gene silencing has been assessed by real-time quantitative PCR at 48 h post-transfection. Selected siRNAs decreased the expression of their target mRNA by at least 50% (Supplementary material online, Table S2 ). Ex vivo cultured aorta were transfected for siRNA using same experimental conditions with the polycationic reagent JET-PEI. Vessels were incubated for 48 h in serum-free DMEM for control or stented aorta before RNA extraction or evaluation for cell proliferation assays by microscopy.
Real-time quantitative PCR
siRNA-mediated Rho GEF silencing was validated by real-time quantitative PCR performed on the iCycler iQ TM Detection System (Bio-Rad S.A., Marnes la Coquette, France) as previously described. 16 
Plasmid transfection
The plasmids were introduced into VSMC with Jet PEI reagent (Polytransfection) according to the manufacturer's recommendations. The wild-type Rho GEF Vav3 (WT-Vav3) and the inactive mutant Y173F-Vav3 were obtained from Dr Charvet. 17 Other plasmids used were RhoA-N19, Rac1-N17, and Cdc42-N17. The Pmax GFP vector was purchased from Amaxa Biosystems (Cologne, Germany). Cells were incubated with or without 0.6 mg/mL of empty (mock) or specific plasmids. The transfection efficiency has been assessed by real-time quantitative PCR. WT-Vav3 and Y173F-Vav3 mutants were expressed to similar levels. Twenty-four hours after transfection, the culture medium was replaced by fresh culture medium and cells were treated then harvested, processed, and analysed.
Immunohistochemistry
Serum-starved VSMC (24 h) were fixed for 30 min in 4% paraformaldehyde, permeabilized for 10 min in 0.5% Triton X-100, and then rinsed in phosphate-buffered saline. Coverslips were then examined with a fluorescence microscope (Eclipse E-600, Nikon, Champigny-sur-Marne, France) and transfected cells were identified as GFP-expressing cells. Rac1 was specifically labelled by a specific anti-Rac1 antibody (BD Biosciences, Le Pont-de-Claix, France) and detected with an alkaline phosphatase-conjugated IgG (Sigma-Aldrich). Images were collected with a cool-SNAP camera (Princeton Instruments, Evry, France) and stored for analysis (Metamorph, Universal Imaging Corp., Buckinghamshire, UK).
Western blot analysis
For the preparation of total lysate, serum-starved VSMC (24 h), stimulated or not, were harvested and homogenized in NETF lysis buffer (NaCl 100 mM, EGTA 2 mM, Tris-HCl 50 mM, 50 mM NaF, pH 7.4, 1% nonidet P-40, 2 mM sodium orthovanadate, and protease inhibitor and phosphate inhibitor mixture (Sigma-Aldrich)). For the membrane fraction preparation, VSMC were homogenized in lysis buffer containing (in mM): 20 Hepes -NaOH, 10 KCl, 10 NaCl, 5 MgCl 2 , 1 dithiothreitol, and protease inhibitors. Nuclei and unlysed cells were removed by low-speed centrifugation. The supernatant was then centrifuged at 100 000 g for 30 min to generate membrane and cytosolic fractions. Proteins were resolved on SDS-PAGE and transferred to nitrocellulose membranes (Amersham Pharmacia Biotech, Orsay, France), which were incubated with specific antibodies for detection of b-actin, vinculin, Rac1, and phosphorylated P21-activated kinase 1 (PAK1). Immunoreactive bands were visualized using horseradish peroxidase-conjugated secondary antibody and subsequent enhanced chemiluminescence (ECL) detection (Amersham Pharmacia Biotech) and then quantified by densitometry analysis using QuantityOne (Bio-Rad).
Cell proliferation assay
Cell proliferation was assessed by both cell counting and 5-bromodeoxyuridine (BrdU) incorporation. After 48 h under different culture conditions, cells were obtained by harvesting the culture with 0.25% trypsin, then counted using a Malassez chamber. For BrdU incorporation assay, the number of BrdU-positive cells was determined after labelling and detection was performed with alkaline phosphatase assay according to the manufacturer's instructions (Roche Applied Science, Meylan, France).
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Cell spreading assay on fibronectin
At 48 h post-transfection, VSMC-expressing mock plasmid, the active Rac mutant Rac1-V12 or WT-Vav3 together with GFP were trypsinized and washed. Dispersed VSMC were then plated onto fibronectin-coated coverslips. At various time points, VSMC were fixed and GFP-positive VSMC were observed by microscopy (Eclipse E-600, Nikon). Mean cell area (Metamorph -Metaview), and the number of spread cells were determined and expressed as percentage of control (mock).
Cell migration assays
For in vitro wound healing assay was performed as previously described. 18 The effects of various agents or plasmids were analysed by addition to culture medium or transfected 24 h before the test. The percentage of cellular recoverage area to the whole wound area was measured to evaluate migration.
Boyden chamber assay was performed as previously described. 18 VSMC, transfected with siRNA or plasmid 48 h before, were trypsinized and washed in serum-free DMEM before plating into a 12-well transwell plate (12 mm diameter, 8 mm pore size, Corning Incorporated Costar, Koolhovenlaan, The Netherlands) at 5Â10 4 cells per/ well. Migration to the lower chamber of the transwell was expressed as the number of cells that had migrated per high-power field (magnification Â400).
Animal model
Wistar-Kyoto rats (300 g) were divided into two groups: an untreated control group and an N v -nitro-L-arginine methyl ester (L-NAME)-treated group receiving the NO synthesis inhibitor L-NAME hydrochloride (Sigma-Aldrich) in drinking water (50 mg/kg/day) for a period of 2 or 14 days. A radio telemetry system (DSI, Saint Paul, MN, USA) was used to monitor mean arterial pressure. Mean arterial pressure was 98 + 8 mmHg under basal condition, and 130 + 2 mmHg and 143 + 7 mmHg after 2 and 14 days of L-NAME administration, respectively (n ¼ 7, P , 0.001) (Supplementary material online, Figure S2 ). Aortas were harvested and separated from adherent connective tissue in sterile physiological salt solution (PSS) (NaCl 130 mM, KCl 5.6 mM, MgCl 2 1 mM, glucose 11 mM, HEPES 10 mM, pH 7.4). The endothelium was carefully removed by gently rubbing the vessel with the tip of small forceps. Arteries of each group were snap-frozen in liquid nitrogen for further studies.
Aorta culture and stenting
Aorta of Wistar-Kyoto rats (300 g) were isolated and dissociated from adherent connective tissue in sterile PSS. The vessels were then cut into two equal segments: one was used as control and the other part receiving a 9 Â 2.5 mm stent (10 atm, 10 s balloon inflation; AMG International GmbH, Raesfeld-Erle, Germany). Artery segments were placed in incubator (378C, 95% air -5% CO 2 ) in 0% FCS -DMEM for 24 -48 h, then washed and snap-frozen in liquid nitrogen and used for mRNA preparation or fixed after BrdU incubation for cell proliferation assay by immunocytochemistry.
Chemicals and drugs
b-Actin antibody was purchased from Sigma. Rabbit polyclonal anti-phospho-PAK1 antibodies were from Cell Signaling Technology (Ozyme, Saint Quentin, France). The anti-Rac1 antibody was from BD transduction laboratories (BD Biosciences, Le Pont-de-Claix, France). All other reagents were purchased from Sigma-Aldrich.
Statistics
All results are expressed as the means + SEM of sample size n. Significance was tested by Student's t-test or Mann-Witney test when appropriate. Data were considered statically significant when P , 0.05.
Results

Vav3 is involved in VSMC proliferation
By quantitative PCR analysis, we have identified 27 Rho GEFs expressed in arterial smooth muscle cells (Supplementary material online, Table S1 and Figure S1 ). Systematic functional analysis of these 27 Rho GEFs by siRNA-mediated silencing indicated that only siRNA targeting the Rho GEF Vav3 inhibited serum (10%)-induced VSMC proliferation ( Figure 1A) . This results was confirmed by the use of two additional siRNA targeting Vav3 that produced a similar inhibition of VSMC proliferation ( Figure 1B) . Vav3 silencing also significantly reduced Ang II (100 nM) and insulin growth factor 1 (IGF1, 100 ng/mL)-induced proliferation ( Figure 1C) . BrdU incorporation assay indicated that the effect of Vav3 silencing was related to an inhibition of VSMC proliferation and not a change in the cell viability ( Figure 1D ).
To further analyse the role of Vav3 in the regulation of VSMC proliferation, we next transfected VSMC with plasmid encoding for WT-Vav3 or the non-activatable/non-phosphorylatable dominantnegative form of Vav3 (Y173F-Vav3). 13, 17, 19 Transfection of WT-Vav3 potentiated serum-induced VSMC proliferation assessed by both cell counting ( Figure 2A ) and BrdU labelling ( Figure 2B ), while Y173F-Vav3 had no effect ( Figure 2A) . The stimulatory effect of WT-Vav3 expression on serum-induced proliferation was lost in VSMC treated with the Src tyrosine kinase family inhibitor SU6656 (2 mM) ( Figure 2C ). The stimulatory action of WT-Vav3 on VSMC proliferation was not only restricted to the effect of serum but was also found for Ang II-and IGF-1-induced proliferation ( Figure 2D ). These results thus suggest that Vav3 activity positively regulated VSMC proliferation through Src-mediated phosphorylation of its Tyr173.
Vav3-mediated VSMC proliferation depends on Rac1 activation
To define the Vav3 target involved in WT-Vav3-mediated proliferation, we next transfected VSMC with dominant-negative forms of Rho proteins. The potentiating effect of WT-Vav3 on VSMC proliferation was not affected by the expression of RhoA-N19 or Cdc42-N17, while it was lost in cells expressing Rac1-N17 ( Figure 3A ). This suggests that the effect of Vav3 on VSMC proliferation was related to activation of Rac1 and that Vav3 in VSMC acts as a Rac1 exchange factor. Indeed, this result is in agreement with cell morphology and Rac1 localization in VSMC-expressing WT-Vav3. WT-Vav3-expressing VSMC displayed extensive lamellipodia, in association with a localized enrichment of Rac1 in these membrane protrusions ( Figure 3B ). In addition, western blot analysis on membrane fraction showed increased membrane-associated Rac1 in VSMC-expressing WT-Vav3, while the total Rac1 expression was not modified ( Figure 3C ). Vav3-mediated Rac1 pathway activation was further confirmed by examination of the activation of the Rac1 target PAKs (p21-activated kinases). Overexpression of WT-Vav3 induced a marked increase in PAK activation both in the absence and in the presence of serum for different times ( Figure 3D ). These results are in agreement with a role of Vav3 as a Rac1 activator in VSMC and the involvement of Rac1 in Vav3-induced stimulation of VSMC proliferation.
Vav3 regulates VSMC proliferation and migration
Vav3 modulates VSMC spreading and morphology
Rac1 is known as a key regulator of cell adhesion and motility. As Vav3 regulates Rac1 signalling activity in VSMC, we assessed whether Vav3 regulated VSMC morphology and spreading. In agreement with the formation of extensive lamellipodia ( Figure 3B ), VSMC-expressing WT-Vav3 showed a marked increase in cell area ( Figure 4A ). Furthermore, spreading assay on fibronectin demonstrated that WT-Vav3 expression modified VSMC adhesion properties. At both 15 and 30 min after plating on fibronectin, VSMC-expressing WT-Vav3 showed accelerated adhesion and spreading illustrated by the increased number of spread cells and the enhancement of mean cell area ( Figure 4B ). The behaviour of WT-Vav3-expressing VSMC is similar to that of VSMC-expressing Rac1-V12 ( Figure 4A and B) . Thus, in agreement with its activating effect on Rac1, Vav3 contributes to VSMC/extracellular matrix interaction and adhesion.
Vav3 stimulates VSMC motility
The in vitro model of VSMC monolayer wounding and restitution was first used to assess the effect of Vav3 on VSMC migration. After scrape wounding, VSMC migrated across the wound edge to fill in the area that was denuded of cell by the scrape ( Figure 5A ). Expression of WT-Vav3 accelerated the wound closure both in the absence and in the presence of serum ( Figure 5A ). The stimulatory effect of WT-Vav3 on VSMC motility was confirmed in Boyden chamber migration assays in the absence and in the presence of serum ( Figure 5B) . In contrast to WT-Vav3, the Y173F-Vav3 mutant did not stimulate VSMC migration indicating that the exchange activity of Vav3 was required ( Figure 5C ). In agreement with this observation, we found that expression of Rac1-V12 mimicked the effect of WT-Vav3 on VSMC migration ( Figure 5C ). Conversely, co-expression of the inactive Rac1-N17 mutant abolished the stimulatory effect of WT-Vav3 on VSMC migration ( Figure 5C ), thus suggesting that the effect of Vav3 on VSMC motility depends on Vav3-mediated Rac1 activation. In the other way, depletion of Vav3 by siRNA induced a significant decrease of VSMC migration compared with scrambled siRNA-treated cells ( Figure 5D ) indicating that active endogenous Vav3 controls VSMC motility.
Vav3 expression and arterial wall remodelling
Since endogenous Vav3 regulates VSMC cell proliferation and migration, we next analysed Vav3 expression in the aorta of hypertensive rats and in stented aorta, two different conditions known to be associated with arterial remodelling related to increased VSMC proliferation and/or migration. Development of hypertension in L-NAME-treated rats was associated with arterial wall remodelling Vav3 regulates VSMC proliferation and migration ( Figure 6A ). The expression of Vav3 mRNA, assessed by real-time quantitative PCR, was significantly increased in aorta of rats treated by L-NAME for 2 days ( Figure 6B ). The increase in the level of Vav3 mRNA was transient and was not observed after 14 days of L-NAME administration ( Figure 6B) . Following ex vivo stent implantation in rat aorta, the expression of Vav3 mRNA was not changed at 24 h but was significantly increased at 48 h post-stenting ( Figure 6C ). BrdU incorporation shows that the rise in Vav3 mRNA level at 48 h was associated with increased vascular cell proliferation in the arterial wall ( Figure 6C ). This stent-induced proliferation was inhibited in arteries treated by Vav3 siRNA that expressed reduced Vav3 mRNA level ( Figure 6C and D) . Taken together, these data thus suggest that arterial wall remodelling processes were associated with increased Vav3 expression, and that Vav3 can participate in vascular cell wall proliferation.
Discussion
In this study, we demonstrate that the Rho GEF Vav3 regulates VSMC proliferation and migration through the activation of Rac1/PAK signalling pathway. We further show that Vav3 expression is increased during vascular wall remodelling and involved in vascular wall cell proliferation.
Vav3 is a member of the Vav family of Rho protein activators. This subfamily of Dbl-Rho GEFs comprised three members in vertebrates, Vav (or Vav1), Vav2, and Vav3, that share a common structural arrangement. Vav proteins share 50-60% sequence homology and similar structural domains including calponin homology, DH, PH, cysteine-rich CR, Src homology 2 and 3 domains. 13 At the expression level, Vav is restricted mostly to haematopoietic cells, but was also detected in a few non-haematopoietic tissues, such as the pancreas, the tooth enamel, and the trophoblast layer. 13 On the other hand, Vav3 shows a much broader expression profile, and Vav2 displays an almost ubiquitous distribution. Data regarding expression and roles of Vav2 and Vav3 in the cardiovascular system are very limited. In endothelial cells, Vav2 and Vav3 have been reported to link the EphA2 receptor to Rho proteins activation and angiogenesis. 20 Vav3 knock-out mice were shown to develop hypertension. 13 However, this did not result from a direct cardiovascular system defect, but was due to hyperactivity of sympathetic neurons. 15 Therefore, this mice model did not allow to address the role of Vav3 in the cardiovascular system. Our study shows that silencing of Vav3 decreased VSMC cell proliferation and migration indicating that Vav3 is expressed and active in VSMC. In addition, the absence of any effect of Vav2 silencing on VSMC functions suggests that Vav proteins are not functionally redundant in VSMC. 
Vav3 regulates VSMC proliferation and migration
The analysis of the catalytic specificities of Vav proteins indicates that they target overlapping, but not identical, spectra of Rho/Rac substrates. Thus, Vav works catalytically on Rac1, Rac2, and RhoG but is significantly less active on RhoA, whereas Vav2 and Vav3 act catalytically on RhoA and RhoG and are less active on Rac1. 13 Here, we found by the use of dominant-negative mutant of Rho proteins that the Vav3 target mediating regulation of VSMC proliferation and migration was Rac1. Our observation is in agreement with data from overexpression of the WT-Vav3 in NIH 3T3 cells that led to a marked activation of Rac1, but no detectable activation of RhoA. 19 Similarly, either Vav2 or Vav3 overexpression in primary microvascular endothelial cells promotes Rac1 activation and cell migration. 20 An essential role of Rac1 in cell migration has been established in a large variety of cell types, including in the cardiovascular system. 21 -23 Rac1 is important for the formation of lamellipodia at the leading edge of the cells and forward movement and is also involved in cell retraction at the trailing edge via its effector PAK. The observations that (i) Vav3 overexpression induced PAK activation, lamellipodia formation, relocalization of Rac1 in protrusions and (ii) that dominant-negative mutant of Rac1 inhibited Vav3-induced migration are therefore in agreement with Rac1 activation and Rac1-mediated cytoskeletal rearrangement and migration downstream of Vav3. The identification of Rac1 as the mediator of Vav3 effect was further strengthened by the inhibitory effect of dominant-negative Rac1 on Vav3-mediated VSMC proliferation. Indeed, it was already known that, in addition to modulation of VSMC motility, Rac1 also regulates VSMC proliferation, mainly through the activation of NADPH oxidases and the production of reactive oxygen species. 24 It has been suggested that at least two distinct pathways may exist downstream of Rac1 (Rac1-PAK-Cyclin D and Rac1-actin-Skp2), both of which are required for efficient Rac1-mediated VSMC cell-cycle progression and proliferation. 20, 25 Vav proteins can be activated by a wide variety of cell surface receptors, including immune receptors, integrins, G protein-coupled receptors, and growth factor receptors, through the phosphorylation of regulatory tyrosines in their amino terminus. Indeed, guanine-nucleotide-exchange activity of all three Vav proteins is modulated through tyrosine phosphorylation by Src and Syk family kinases. 13, 19 Actually, Vav3 has been shown to become rapidly tyrosine phosphorylated, in particular at Tyr173, and associate with several tyrosine kinase receptors and downstream signalling molecules in different cell types. 19, 26 Our results showing the inhibitory effect of the Src inhibitor SU6656 and the inability of the Vav3 regulates VSMC proliferation and migration phosphoresistant mutant Y173F-Vav3 to induce VSMC response strongly support a role for the phosphorylation of the Tyr173 in the activation of Vav3 in VSMC. This is in agreement with the observation that Vav3 is involved in VSMC proliferation and migration induced by serum, Ang II, and IGF, all known to act through stimulation of tyrosine kinases. Vav3 thus appears as a convergent target for multiple tyrosine kinase-dependent signalling. In addition to the in vitro effects of Vav3 observed on VSMC proliferation, adhesion, and migration, our results show the up-regulation of Vav3 transcripts in stented arteries and arteries from hypertensive animals, and the inhibition of vascular wall cell proliferation by Vav3 siRNA in stented arteries. These observations strongly suggest an in vivo role of Vav3 in arterial wall remodelling. With the identification of Rac1 as the Vav3 target in VSMC, our results are thus in agreement with the activation of Rac1 and its involvement in VSMC proliferation described in balloon dilated arteries 20 and support a role of Vav3 as an upstream Rac1 activator during vascular wall remodelling process. The stimulus for Vav3/Rac1 activation in vivo is most likely the release of growth factors and remodelling of the vascular extracellular matrix since these occur after vascular injury and have been shown to activate Vav3/Rac1 in other systems. 13, 27, 28 In summary, our study establishes for the first time a role of a nonregulators of G protein signaling (RGS) Rho GEF in VSMC. Our data demonstrate that the Rho GEF Vav3 controls VSMC proliferation and migration both in culture and during arterial wall remodelling. We identified Vav3 as a convergent point mediating Rac1 activation in response to different upstream mediators that promote VSMC proliferation and migration. Vav3 thus appears as a new potential therapeutic target that could be used to limit vascular proliferative diseases.
Supplementary material
Supplementary material is available at Cardiovascular Research online.
